par Partridge, Ann H;Niman, Samuel M;Ruggeri, Monica;Peccatori, Fedro Alessandro;Azim, Hatem A;Colleoni, Marco Angelo;Saura, Cristina;Shimizu, Chikako;Sætersdal, Anna Barbro;Kroep, Judith R;Mailliez, Audrey;Warner, Ellen;Borges, Virginia F;Amant, Frédéric;Gombos, Andrea ;Kataoka, Akemi;Rousset-Jablonski, Christine;Borstnar, Simona;Takei, Junko;Lee, Jeong E;Walshe, Janice M;Ruíz-Borrego, Manuel;Moore, Halle C F;Saunders, Christobel;Bjelic-Radisic, Vesna;Susnjar, Snezana;Cardoso, Fatima ;Smith, Karen L;Ferreiro, Teresa;Ribi, Karin;Ruddy, Kathryn;Kammler, Roswitha;El-Abed, Sarra;Viale, Giuseppe;Piccart-Gebhart, Martine ;Korde, Larissa A;Goldhirsch, Aron;Gelber, Richard D;Pagani, Olivia;International Breast Cancer Study Group, ;POSITIVE Trial Collaborators,
Référence The New England journal of medicine, 388, 18, page (1645-1656)
Publication Publié, 2023-05
Référence The New England journal of medicine, 388, 18, page (1645-1656)
Publication Publié, 2023-05
Article révisé par les pairs
Résumé : | Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. |